AIM: The aim of the study was to analyze the occurrence of abnormal gene copy numbers of all HER oncogenes and to correlate these alterations to other clinicopathological variables in a consecutive series of 225 breast cancer patients. METHODS: Gene copy number of HER oncogenes was analyzed with double differential polymerase chain reaction (ddPCR). Statistical analysis was performed with a set of nonparametric tests. RESULTS: Sixty-five percent of the tumors contained abnormal gene copy number of at least one HER oncogene. Alterations of at least two oncogenes were found in 31% of cases. The correlations between average gene copy numbers (AGCNs) of particular HER oncogenes were much stronger in node positive compared to node-negative tumors. Deletions of EGFR were associated with the lack of steroid hormone receptors. The HER3 and HER4 amplifications were more common in well differentiated tumors. CONCLUSIONS: Our results indicate a key role of HER heterodimers in tumor progression and confirm earlier data that HER2 is the preferred partner for other HER oncogenes in this process. Deletions of EGFR were associated with unfavorable characteristics, whereas HER3 and HER4 amplifications may be linked with less aggressive phenotypes.
AIM: The aim of the study was to analyze the occurrence of abnormal gene copy numbers of all HER oncogenes and to correlate these alterations to other clinicopathological variables in a consecutive series of 225 breast cancerpatients. METHODS: Gene copy number of HER oncogenes was analyzed with double differential polymerase chain reaction (ddPCR). Statistical analysis was performed with a set of nonparametric tests. RESULTS: Sixty-five percent of the tumors contained abnormal gene copy number of at least one HER oncogene. Alterations of at least two oncogenes were found in 31% of cases. The correlations between average gene copy numbers (AGCNs) of particular HER oncogenes were much stronger in node positive compared to node-negative tumors. Deletions of EGFR were associated with the lack of steroid hormone receptors. The HER3 and HER4 amplifications were more common in well differentiated tumors. CONCLUSIONS: Our results indicate a key role of HER heterodimers in tumor progression and confirm earlier data that HER2 is the preferred partner for other HER oncogenes in this process. Deletions of EGFR were associated with unfavorable characteristics, whereas HER3 and HER4 amplifications may be linked with less aggressive phenotypes.
Authors: H Buerger; F Gebhardt; H Schmidt; A Beckmann; K Hutmacher; R Simon; R Lelle; W Boecker; B Brandt Journal: Cancer Res Date: 2000-02-15 Impact factor: 12.701
Authors: Sam M Wiseman; Nikita Makretsov; Torsten O Nielsen; Blake Gilks; Erika Yorida; Maggie Cheang; Dmitry Turbin; Karen Gelmon; David G Huntsman Journal: Cancer Date: 2005-05-01 Impact factor: 6.860
Authors: Jeffrey S Ross; Jonathan A Fletcher; Gerald P Linette; James Stec; Edward Clark; Mark Ayers; W Fraser Symmans; Lajos Pusztai; Kenneth J Bloom Journal: Oncologist Date: 2003
Authors: J C Delarue; S Friedman; H Mouriesse; F May-Levin; H Sancho-Garnier; G Contesso Journal: Breast Cancer Res Treat Date: 1988-05 Impact factor: 4.872
Authors: Ellen Q Ingalla; Jamie K Miller; Jessica H Wald; Heather C Workman; Rouminder P Kaur; Lily Yen; William H D Fry; Alexander D Borowsky; Lawrence J T Young; Colleen Sweeney; Kermit L Carraway Journal: J Biol Chem Date: 2010-07-13 Impact factor: 5.157
Authors: Anna J Zaczek; Aleksandra Markiewicz; Barbara Seroczynska; Jaroslaw Skokowski; Janusz Jaskiewicz; Tadeusz Pienkowski; Wojciech P Olszewski; Jolanta Szade; Piotr Rhone; Marzena Welnicka-Jaskiewicz; Jacek Jassem Journal: Oncologist Date: 2012-08-07
Authors: Renata Veselska; Jan Skoda; Tomas Loja; Karel Zitterbart; Zdenek Pavelka; Jana Smardova; Iveta Valaskova; Marketa Hermanova; Jaroslav Sterba Journal: Childs Nerv Syst Date: 2010-02-27 Impact factor: 1.475
Authors: Edith A Perez; Monica M Reinholz; David W Hillman; Kathleen S Tenner; Matthew J Schroeder; Nancy E Davidson; Silvana Martino; George W Sledge; Lyndsay N Harris; Julie R Gralow; Amylou C Dueck; Rhett P Ketterling; James N Ingle; Wilma L Lingle; Peter A Kaufman; Daniel W Visscher; Robert B Jenkins Journal: J Clin Oncol Date: 2010-08-09 Impact factor: 44.544
Authors: Edith A Perez; Frederick L Baehner; Steven M Butler; E Aubrey Thompson; Amylou C Dueck; Farid Jamshidian; Diana Cherbavaz; Carl Yoshizawa; Steven Shak; Peter A Kaufman; Nancy E Davidson; Julie Gralow; Yan W Asmann; Karla V Ballman Journal: Breast Cancer Res Date: 2015-10-01 Impact factor: 6.466
Authors: Andrea Sassen; Justine Rochon; Peter Wild; Arndt Hartmann; Ferdinand Hofstaedter; Stephan Schwarz; Gero Brockhoff Journal: Breast Cancer Res Date: 2008-01-08 Impact factor: 6.466